Shuttle Pharmaceuticals Holdings, Inc. / "Research and Development" | Tables in SEC filings

SHPH Shuttle Pharmaceuticals Holdings, Inc.

IPO registration

	2024		2023		2024		2023
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

Revenue	$	-	$	-	$	-	$	-

Operating expenses
Research and development		1,400,564		1,045,177		2,632,387		2,806,644
General and administrative		328,995		265,553		963,642		730,186
Legal and professional		1,322,002		288,416		2,323,013		1,072,728
Total operating expenses		3,051,561		1,599,146		5,919,042		4,609,558

Loss from operations		(3,051,561)		(1,599,146)		(5,919,042)		(4,609,558)

Other income (expense)
Interest expense - related parties		(2,137)		-		(2,137)		(6,825)
Interest expense		(270,538)		(623,465)		(1,198,738)		(1,952,147)
Interest income		2,524		20,765		38,135		56,720
Finance fee		-		-		-		(104,245)
Change in fair value of derivative liabilities		286,316		442,900		340,405		2,118,175
Change in fair value of warrant liabilities, as restated
Gain on sale of marketable securities		56,398		-		100,118		1,744
Change in fair value of marketable securities		(42,898)		9,606		(71,568)		21,134
Loss on settlement of convertible debt		(762,186)		(43,414)		(833,501)		(477,221)
Gain on settlement of accounts payable
Gain on forgiveness of Paycheck Protection Program note payable
Total other income (expense)		(732,521)		(193,608)		(1,627,286)		(342,665)

Net loss attributable to common stockholders	$	(3,784,082)	$	(1,792,754)	$	(7,546,328)	$	(4,952,223)

Dividend on Series A Convertible Preferred Stock, as restated
Deemed dividend on extinguishment of Series A Convertible Preferred Stock, as restated
Deemed dividend on modification of equity-classified warrants, as restated
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated
Net loss attributable to common stockholders
Weighted average common shares outstanding - basic and diluted		2,384,177		1,969,904		2,189,366		1,820,006
Net loss per shares - basic and diluted	$	(1.59)	$	(0.91)	$	(3.45)	$	(2.72)

Consolidated Statement of Operations for the year ended December 31, 2022	As Reported		Adjustment		As Restated
Research and development, net of contract expense reimbursements	$	1,148,712	$	(101,327)	$	1,047,385
General and administrative		538,796		(65,082)		473,714
Legal and professional		866,770		(44,043)		822,727
Net loss from operations		(2,554,278)		210,452		(2,343,826)
Interest expenses		(917,879)		489,191		(428,688)
Financing fee		—		(189,912)		(189,912)
Change in fair value of derivative liabilities		—		(189,000)		(189,000)
Change in fair value of warrant liabilities		94,025		(492,700)		(398,675)
Loss on extinguishment of debt		—		(1,795,652)		(1,795,652)
Net loss		(3,028,448)		(1,967,621)		(4,996,069)
Dividend on Series A Preferred Stock		(71,009)		(331,055)		(402,064)
Deemed dividend on extinguishment of Series A Preferred Stock		—		(439,427)		(439,427)
Deemed dividend on modification of equity-classified warrants, as restated		—		(941,000)		(941,000)
Deemed contribution on conversion of preferred stock and settlement of preferred stock dividends, as restated		—		31,423		31,423
Net loss attributable to common stockholders		(3,099,457)		(3,647,680)		(6,747,137)
Net loss per shares - basic and diluted	$	(2.32)	$	(2.72)	$	(5.04)

	Years Ended
	December 31,
	2023		2022		Change		%
			(as restated)
Revenue	$	—	$	—	$	—		—
Operating expenses:
Research and development, net of contract expense reimbursements, as restated		3,517,093		1,047,385		2,469,708		236	%
General and administrative, as restated		1,046,854		473,714		573,140		121	%
Legal and professional, as restated		1,328,435		822,727		505,708		61	%
Total operating expenses and loss of operations, as restated		5,892,382		2,343,826		3,548,556		151	%

Other income (expense):
Interest expense - related parties		(6,825)		(52,010)		45,185		(87	)%
Interest expense, as restated		(2,484,193)		(428,688)		(2,055,505)		479	%
Interest income		79,117		—		79,117		100	%
Finance fee, as restated		(104,245)		(189,912)		85,667		(45	)%
Change in fair value of derivative liabilities, as restated		2,216,488		(189,000)		2,405,488		1,273	%
Change in fair value of warrant liabilities, as restated		—		(398,675)		398,675		100	%
Gain on sale of marketable securities		4,970		—		4,970		100	%
Change in fair value of marketable securities		71,568		—		71,568		100	%
Loss on settlement of convertible debt, as restated		(477,221)		(1,795,652)		1,318,431		(73	)%
Gain on settlement of accounts payable		—		328,687		(328,687)		(100	)%
Gain on forgiveness of Paycheck Protection Program note payable		—		73,007		(73,007)		(100	)%
Total other expense, as restated		(700,341)		(2,652,243)		1,951,902		(74	)%
Net loss, as restated	$	(6,592,723)	$	(4,996,069)		(1,596,654)		32	%

Table search / Shuttle Pharmaceuticals Holdings, Inc. / "Research and Development"

53 results

Top filers

Top filing types

Recent filing years